In the Past 30 Days...
PER WEEK
PER POST
PER POST
In the last 30 days, the average company in this landscape has grown their audience by <0.1%. Abbott grew faster than everyone else, with 0.6% growth! On average, each post in this landscape earns more than 156.6 engagements. Abbott is topping the charts with more than 1.32k engagements per post on their 14 posts in the last 30 days.
573 Likes • 12 Comments
Team Abbott is celebrating the londonmarathon by inspiring good health through running, but staying healthy looks different for everyone. We asked London Marathon goers how they stay healthy through movement, nutrition and more. 🇬🇧🏃♀️🍎🧘
217 Likes • 1 Comments
The next generation of leaders showed off their budding talents this #TakeYourChildtoWorkDay! Swipe to see moments from our action-packed day with our colleagues’ kids, from perfecting a headshot, watching a science demo, performing experiments, creating rock art, directing videos in our studio and enjoying sweet treats in our cafeteria.
174 Likes • 4 Comments
“The flexibility of my job allows me to be all the versions of Carlos that I am: the Carlos of Novartis, the singer, the athlete, the runner, the mountaineer and Carlos the family man. It allows me to be all parts of myself and dedicate time to them all.” Carlos, Benefits Administration Expert
134 Likes • 0 Comments
Interesting fact: Mass spectrometry is a powerful technique that can detect molecules in a sample even at a very low concentration, empowering personalised medicine. Curious to learn more? Discover Alice Schlichtiger and her team’s innovative work in mass spectrometry to transform the future of patient care. Read her amazing story in our new series! Link in bio. #massspectrometry #innovation …
121 Likes • 6 Comments
14 days to go until Eurovision! 🎉 Our reporter Sinja is staying close to the action in Basel—catching surprise moments like the Novartis Choir’s beautiful rendition of “Z'Basel am mym Rhy”. 🚋 🎶 eurovisioncountdown #Eurovision2025 #ESC2025 #Eurovision #Basel
85 Reactions • 11 Comments • 14 Shares
Brains are complicated. And for people with Parkinson’s disease, neurons that aren't working normally can cause uncontrollable tremors that can make everyday tasks extremely complicated. Health tech, like our Liberta RC DBS system, can help people get control back. Learn more: https://abbo.tt/3YdU5eS ISI: https://abbo.tt/NeuromodulationISI
44 Reactions • 11 Comments • 5 Shares
While you’re doing your spring cleaning this month, don’t forget that today is #NationalDrugTakeBackDay! – the perfect time to sift through and discard your expired or unneeded prescriptions and over-the-counter medications. Visit this link https://cvs.co/4hV7101 for disposal locations.
47 Reactions • 7 Comments • 4 Shares
Melissa, a nurse turned clinical scientist in our oncology R&D group, is developing lifesaving cancer therapies and redefining nursing's role in research. With a focus on accessibility in clinical trials, she’s paving the way for more effective treatments. Discover how her journey is transforming healthcare: https://social.jnj.com/3EDmm7O
38 Reactions • 13 Comments • 2 Shares
Struggling with nasal congestion, dryness, or allergies? Saline nasal sprays can be a game-changer! 💧 Check out our article to learn more:
34 Reactions • 4 Comments • 5 Shares
“The flexibility of my job allows me to be all the versions of Carlos that I am: the Carlos of Novartis, the singer, the athlete, the runner, the mountaineer and Carlos the family man. It allows me to be all parts of myself and dedicate time to them all.” Carlos, Benefits Administration Expert
31 Likes • 8 Retweets
The @US_FDA approved a new indication for our CDK4/6 inhibitor as part of a triplet combination therapy for the treatment of certain patients with PIK3CA-mutated, HR+, HER2-, metastatic #BreastCancer. Learn more: on.pfizer.com/3YN3vxQ pic.x.com/GfhinOwio6
22 Likes • 5 Retweets
At #AUA25, we announced full event-free survival results from our pivotal Phase 3 trial in patients with BCG-naïve, high-risk non-muscle invasive #BladderCancer (NMIBC). Learn more: on.pfizer.com/42OGhbW pic.x.com/wLGtnP0CnB
22 Likes • 4 Retweets
We’re challenging our experts to make #cancer easier to understand for friends, doctors and scientists. Watch a Pfizer scientist explain resistance in cancer treatment to different audiences in episode 1 of our new series, Science Made Simple, here: on.pfizer.com/3ESruVE pic.x.com/RZofUGrxZc
20 Likes • 7 Retweets
In @ScienceMagazine's latest issue, our Head of Early-Stage Development at Pfizer Oncology highlights new data from our leading next-generation ADC pipeline at #AACR25 and how her team is positioned to advance the industry’s most extensive ADC portfolio: on.pfizer.com/42GhxCH pic.x.com/mfD4NAT954
14 Likes • 2 Retweets
#MEDIA - We are pleased to share that our Phase III study results, published in @NEJM, show a significant reduction in #influenza transmission from infected individuals to household members. spkl.io/6011fItbB $ROG $RHHBY pic.x.com/nVrG3M1EeW
The Social Media Benchmark Report
Ready to see how you stack up to your industry’s top social performers? Review the latest metrics on channels, engagement, post types, and more.